A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

Inclusion Criteria: * Pathologic diagnosis of pancreatic carcinoma * Radiologic evidence of hepatic metastasis with at least one lesion \> 2.0 cm that is amenable to ultrasound or CT guided intra-tumoral DC injection * Age \> 18 * Life expectancy \> 3 months * Karnofsky Performance Status \> 70% * Patients must not have received any anti-neoplastic chemotherapy, immunotherapy or radiotherapy for the four weeks preceding entry onto the study (six weeks for nitrosoureas and mitomycin C). * Adequate baseline hematopoietic function defined as WBC (white blood cell) \> 3000/mm3, hemoglobin \> 9g/dl, and platelet count \> 100,000/mm3. * Adequate baseline organ function defined as creatinine \< 2.0, total bilirubin \< 2.0 mg/dl * Patients taking warfarin are not eligible. Adequate coagulation function defined as PT (prothrombin time) \< 15, INR \< 1.5 and PTT (partial thromboplastin time) \< 35. * Ability to give informed consent Exclusion Criteria: * Previous anti-tumor vaccine therapy * Prior hepatic irradiation * Known brain metastases * History of prior autoimmune diseases (e.g. SLE (systemic lupus erythematosus), rheumatoid arthritis, myasthenia gravis) * Regular corticosteroid use within the past one year or any corticosteroid use in the four weeks preceding study entry * Evidence of HIV infection, AIDS, Hepatitis B or Hepatitis C infection * Active bacterial, fungal or viral infection * Pregnancy or lactation; women of childbearing potential and men must agree to use effective contraception during the course of this clinical trial * Uncontrolled or unstable medical conditions including angina, arrhythmias, bleeding, or thromboembolic conditions, * Any medical or psychiatric illness that might compromise the patients ability to tolerate treatment